浙江诚意药业股份有限公司 关于 2025 年第三季度业绩说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江诚意药业股份有限公司（以下简称"公司"）于 2025 年 11 月 26 日 9:00-10:00 在上海证券交易所上证路演中心 https://roadshow.sseinfo.com/通 过网络互动方式召开 2025 年第三季度业绩说明会。现将有关事项公告如下： 证券代码：603811 证券简称：诚意药业 公告编号：2025-061 一、业绩说明会召开情况 2025 年 10 月 28 日，公司在上海证券交易所网站（www.sse.com.cn）及指定 信息媒体披露了《浙江诚意药业股份有限公司关于召开 2025 年第三季度业绩说明 会的公告》（公告编号：2025-059）。 2025 年 11 月 26 日 9:00-10:00，公司总经理赵春建先生、销售副总经理颜丽 娜女士、研发副总经理罗飞跃先生、董事会秘书柯泽慧女士、财务总监吕孙战先生 和独立董事黄明先生出席了本次业绩说明会。与投资者进行互 ...

Group 1 - The core viewpoint of the announcement is that the major shareholders of Zhejiang Chengyi Pharmaceutical Co., Ltd. have reduced their holdings, which does not trigger a mandatory bid or affect the company's control structure [1][2]. - As of the announcement date, shareholder Yan Xiaoling has reduced her holdings by 349,722 shares, while Wenzhou Dongtou Chengyi Microfinance Co., Ltd. has reduced its holdings by 2,164,900 shares, totaling a reduction of 2,514,622 shares, which accounts for 0.77% of the company's total share capital [1]. - Following this reduction, the combined shareholding of controlling shareholder Yan Yiyi and his concerted actions decreased from 81,067,702 shares to 78,553,080 shares, resulting in a shareholding ratio drop from 24.77% to 24.00% [1]. Group 2 - The reduction in holdings is part of a previously disclosed plan and does not involve any changes to the company's governance structure or operational continuity [2]. - The reduction aligns with the commitments made by the information disclosure obligors and does not harm the interests of the company or its shareholders [2]. - The reduction plan has not yet been fully implemented as of the announcement date [2].

证券代码：603811 证券简称：诚意药业 公告编号：2025-060 浙江诚意药业股份有限公司 关于控股股东及其一致行动人权益变动 触及 1%刻度的提示性公告 颜贻意及其一致行动人温州市洞头区诚意小额贷款股份有限公司和颜 晓玲保证向本公司提供的信息真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息 一致。 一、 信息披露义务人及其一致行动人的基本信息 信息披露义务人名称 投资者身份 统一社会信用代码 颜贻意 ☑ 控股股东/实控人 □ 控股股东/实控人的一致 行动人 □ 其他直接持股股东 □ _____________ ☑ 不适用 重要内容提示： 权益变动方向 比例增加□ 比例减少☑ 权益变动前合计比例 24.77% 权益变动后合计比例 24.00% 本次变动是否违反已作出的承 诺、意向、计划 是□ 否☑ 是否触发强制要约收购义务 是□ 否☑ 二、 权益变动触及 1%刻度的基本情况 截至本公告披露日，颜晓玲女士通过集中竞价方式减持公司股份 349,722 股，温州市洞头区诚意小额贷款股份有限公司通过集中竞价和大宗交易方式减持 公司股份 2,1 ...

Summary of Key Points Core Viewpoint - Chengyi Pharmaceutical announced a significant reduction in shareholding by major shareholders, indicating a shift in ownership dynamics within the company [2]. Group 1: Shareholding Changes - Ms. Yan Xiaoling reduced her shareholding by 349,722 shares through centralized bidding [2]. - Wenzhou Dongtou Chengyi Microfinance Co., Ltd. reduced its holdings by 2,164,900 shares through centralized bidding and block trading [2]. - The total reduction in shares by these shareholders amounted to 2,514,622 shares, representing 0.77% of the company's total share capital [2]. Group 2: Impact on Major Shareholders - Following the share reductions, the controlling shareholder, Mr. Yan Yiyi, and his concerted parties now hold a total of 78,553,080 shares, down from 81,067,702 shares [2]. - The combined shareholding percentage of Mr. Yan and his concerted parties decreased from 24.77% to 24.00% [2].

格隆汇11月14日丨诚意药业(603811.SH)公布，截至本公告披露日，颜晓玲女士通过集中竞价方式减持 公司股份349,722股，温州市洞头区诚意小额贷款股份有限公司通过集中竞价和大宗交易方式减持公司 股份216.49万股，上述股东累计减持公司股份251.46万股，占公司总股本的0.77%。本次权益变动后， 控股股东颜贻意先生及其一致行动人合计持有公司股份数量由81,067,702股减少至78,553,080股，合计持 股比例由24.77%减少至24.00%，适用权益变动触及1%的整倍数情形。 ...

格隆汇11月14日丨诚意药业(603811.SH)公布，截至本公告披露日，颜晓玲女士通过集中竞价方式减持 公司股份349,722股，温州市洞头区诚意小额贷款股份有限公司通过集中竞价和大宗交易方式减持公司 股份216.49万股，上述股东累计减持公司股份251.46万股，占公司总股本的0.77%。本次权益变动后， 控股股东颜贻意先生及其一致行动人合计持有公司股份数量由81,067,702股减少至78,553,080股，合计持 股比例由24.77%减少至24.00%，适用权益变动触及1%的整倍数情形。 ...

Core Viewpoint - The controlling shareholder of Chengyi Pharmaceutical, Yan Yiyi, and his concerted parties have reduced their shareholding from 24.77% to 24% as of the announcement date [1] Shareholding Changes - Yan Xiaoling reduced her holdings by 349,722 shares through centralized bidding on October 30, 2025 [1] - Wenzhou Dongtou Chengyi Microfinance Co., Ltd. reduced its holdings by 2,164,900 shares through centralized bidding and block trading from November 7 to 14, 2025 [1] - The total reduction amounts to 2,514,622 shares, representing 0.77% of the total share capital [1] Impact on Control and Operations - This change in equity is part of a planned reduction and does not lead to a change in the actual controller [1] - The reduction will not affect the company's operations [1]

Summary of Key Points Core Viewpoint - Chengyi Pharmaceutical experienced a slight decline in stock price, closing at 11.65 yuan, with a notable block trade occurring on November 7, 2023 [1] Trading Activity - The stock saw a block trade involving 1 million shares, totaling 11.42 million yuan, with a transaction price of 11.42 yuan per share, reflecting a premium rate of -1.97% [1] - The buyer was Guotai Junan Securities Co., Ltd., while the seller was Guojin Securities Co., Ltd. [1] Recent Performance - Over the past three months, the stock has recorded a total block trade amounting to 11.42 million yuan [1] - In the last five trading days, the stock has declined by 2.18%, with a net outflow of 33.50 million yuan in principal funds [1]

Group 1 - The company stated that its eicosapentaenoic acid ethyl ester soft capsules are sourced from external suppliers, indicating that it is not affected by the raw material supply issues [2] - The pharmaceutical-grade EPA raw material is currently undergoing technical upgrades and has not yet been submitted for approval [2]

Core Viewpoint - Chengyi Pharmaceutical (603811) has confirmed that the raw materials for its approved product, ethyl eicosapentaenoate soft capsules, are currently sourced externally and is undergoing workshop compliance inspection, with expected sales starting in 2026 [1] Group 1 - The company has received approval for ethyl eicosapentaenoate soft capsules [1] - The raw materials for this product are being procured from external suppliers [1] - The product is currently in the workshop compliance inspection phase [1] - Sales are anticipated to begin in 2026 [1]